Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models
<p><strong>Purpose:</strong> DNA polymerase theta (Polθ, encoded by the POLQ gene) is a DNA repair enzyme critical for microhomology mediated end joining (MMEJ). Polθ has limited expression in normal tissues but is frequently overexpressed in cancer cells and, therefore, represents...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Association for Cancer Research
2023
|
_version_ | 1826310621887463424 |
---|---|
author | Rodriguez-Berriguete, G Ranzani, M Prevo, R Puliyadi, R Machado, N Bolland, HR Millar, V Ebner, D Boursier, M Cerutti, A Cicconi, A Galbiati, A Grande, D Grinkevich, V Majithiya, J Piscitello, D Rajendra, E Stockley, M Boulton, SJ Heald, R Hammond, EM Smith, GCM Robinson, H Higgins, GS |
author_facet | Rodriguez-Berriguete, G Ranzani, M Prevo, R Puliyadi, R Machado, N Bolland, HR Millar, V Ebner, D Boursier, M Cerutti, A Cicconi, A Galbiati, A Grande, D Grinkevich, V Majithiya, J Piscitello, D Rajendra, E Stockley, M Boulton, SJ Heald, R Hammond, EM Smith, GCM Robinson, H Higgins, GS |
author_sort | Rodriguez-Berriguete, G |
collection | OXFORD |
description | <p><strong>Purpose:</strong>
DNA polymerase theta (Polθ, encoded by the POLQ gene) is a DNA repair enzyme critical for microhomology mediated end joining (MMEJ). Polθ has limited expression in normal tissues but is frequently overexpressed in cancer cells and, therefore, represents an ideal target for tumor-specific radiosensitization. In this study we evaluate whether targeting Polθ with novel small-molecule inhibitors is a feasible strategy to improve the efficacy of radiotherapy.</p>
<p><strong>Experimental Design:</strong>
We characterized the response to Polθ inhibition in combination with ionizing radiation in different cancer cell models in vitro and in vivo.</p>
<p><strong>Results:</strong>
Here, we show that ART558 and ART899, two novel and specific allosteric inhibitors of the Polθ DNA polymerase domain, potently radiosensitize tumor cells, particularly when combined with fractionated radiation. Importantly, noncancerous cells were not radiosensitized by Polθ inhibition. Mechanistically, we show that the radiosensitization caused by Polθ inhibition is most effective in replicating cells and is due to impaired DNA damage repair. We also show that radiosensitization is still effective under hypoxia, suggesting that these inhibitors may help overcome hypoxia-induced radioresistance. In addition, we describe for the first time ART899 and characterize it as a potent and specific Polθ inhibitor with improved metabolic stability. In vivo, the combination of Polθ inhibition using ART899 with fractionated radiation is well tolerated and results in a significant reduction in tumor growth compared with radiation alone.</p>
<p><strong>Conclusions:</strong>
These results pave the way for future clinical trials of Polθ inhibitors in combination with radiotherapy.</p> |
first_indexed | 2024-03-07T07:54:39Z |
format | Journal article |
id | oxford-uuid:82663df8-f5e9-4433-80bd-20a96271b182 |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-07T07:54:39Z |
publishDate | 2023 |
publisher | American Association for Cancer Research |
record_format | dspace |
spelling | oxford-uuid:82663df8-f5e9-4433-80bd-20a96271b1822023-08-08T16:33:04ZSmall-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical modelsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:82663df8-f5e9-4433-80bd-20a96271b182EnglishSymplectic ElementsAmerican Association for Cancer Research2023Rodriguez-Berriguete, GRanzani, MPrevo, RPuliyadi, RMachado, NBolland, HRMillar, VEbner, DBoursier, MCerutti, ACicconi, AGalbiati, AGrande, DGrinkevich, VMajithiya, JPiscitello, DRajendra, EStockley, MBoulton, SJHeald, RHammond, EMSmith, GCMRobinson, HHiggins, GS<p><strong>Purpose:</strong> DNA polymerase theta (Polθ, encoded by the POLQ gene) is a DNA repair enzyme critical for microhomology mediated end joining (MMEJ). Polθ has limited expression in normal tissues but is frequently overexpressed in cancer cells and, therefore, represents an ideal target for tumor-specific radiosensitization. In this study we evaluate whether targeting Polθ with novel small-molecule inhibitors is a feasible strategy to improve the efficacy of radiotherapy.</p> <p><strong>Experimental Design:</strong> We characterized the response to Polθ inhibition in combination with ionizing radiation in different cancer cell models in vitro and in vivo.</p> <p><strong>Results:</strong> Here, we show that ART558 and ART899, two novel and specific allosteric inhibitors of the Polθ DNA polymerase domain, potently radiosensitize tumor cells, particularly when combined with fractionated radiation. Importantly, noncancerous cells were not radiosensitized by Polθ inhibition. Mechanistically, we show that the radiosensitization caused by Polθ inhibition is most effective in replicating cells and is due to impaired DNA damage repair. We also show that radiosensitization is still effective under hypoxia, suggesting that these inhibitors may help overcome hypoxia-induced radioresistance. In addition, we describe for the first time ART899 and characterize it as a potent and specific Polθ inhibitor with improved metabolic stability. In vivo, the combination of Polθ inhibition using ART899 with fractionated radiation is well tolerated and results in a significant reduction in tumor growth compared with radiation alone.</p> <p><strong>Conclusions:</strong> These results pave the way for future clinical trials of Polθ inhibitors in combination with radiotherapy.</p> |
spellingShingle | Rodriguez-Berriguete, G Ranzani, M Prevo, R Puliyadi, R Machado, N Bolland, HR Millar, V Ebner, D Boursier, M Cerutti, A Cicconi, A Galbiati, A Grande, D Grinkevich, V Majithiya, J Piscitello, D Rajendra, E Stockley, M Boulton, SJ Heald, R Hammond, EM Smith, GCM Robinson, H Higgins, GS Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models |
title | Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models |
title_full | Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models |
title_fullStr | Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models |
title_full_unstemmed | Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models |
title_short | Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models |
title_sort | small molecule polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models |
work_keys_str_mv | AT rodriguezberrigueteg smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT ranzanim smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT prevor smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT puliyadir smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT machadon smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT bollandhr smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT millarv smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT ebnerd smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT boursierm smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT ceruttia smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT cicconia smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT galbiatia smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT granded smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT grinkevichv smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT majithiyaj smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT piscitellod smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT rajendrae smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT stockleym smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT boultonsj smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT healdr smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT hammondem smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT smithgcm smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT robinsonh smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels AT higginsgs smallmoleculepolthinhibitorsprovidesafeandeffectivetumorradiosensitizationinpreclinicalmodels |